Close Menu

Breaking News

The researchers achieved RNA-guided gene editing in multiple human cell lines with high specificity and efficiencies of up to 50 percent.

The new system, called BODE 2, will launch at the end of this year and will replace the existing BODE for the analysis of "big omics" data for research.

The pilot seeks to enroll 100 All of Us participants who are pregnant into the ongoing NICHD's PregSource initiative, which collects patient-reported data.

PTC Therapeutics is developing a gene therapy for the rare genetic disease AADC deficiency, which impacts the production of two key neurotransmitters.

Last week, GenomeWeb's readers were most interested in Illumina's proposal to offer perpetual, royalty-free licenses to Pacific Biosciences' intellectual property.

BD said TRC Capital Investment had made an unsolicited offer to BD shareholders to buy up to 500,000 shares of BD's stock at a price below the current market value.

The firm said it has received several "conditional, non-binding indications of interest" from potential merger or acquisition partners.

News items for the week of Nov. 11.

Mitochondrial sequences suggest some haplogroups found in Finland today arrived in the region pre-Iron Age, though population distributions have shifted.

The Tucson, Arizona-based company previously raised $20 million through a public offering of its shares and a purchase deal with certain investors.

Medley Genomics' software, called HotNet2, assesses tumor genomic heterogeneity from large-scale sequencing datasets across patient cohorts.

The company incurred a net loss of $5.2 million, or $.10 per share, slightly exceeding the $.09 per share loss that analysts had predicted on average.

The firm will use funds from the round, led by the Midlands Engine Investment Fund, to develop its optical point-of-care diagnostic testing platform.

By uncovering mismatches between Y chromosomes and genealogies, researchers estimated historical rates of extra-pair paternity in Western Europe.

Genotypes for more than 12,000 individuals from the Americas revealed contributions from European colonization, the Atlantic slave trade, and other migrations.

The partners will evaluate circulating tumor cell-based biomarker panels as potential new tests for use on Ikonisys' Ikoniscope fluorescence microscopy system.

Sequencing and other experiments on barcoded Plasmodium berghei mutant strains helped researchers narrow in on key metabolic pathways in the parasite's liver stage.

The company said it intends to use net proceeds from the offering to support development and commercialization for its DetermaVu and Razor assays.

The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.

JP Morgan noted that it sees potential for new management to "reset the bar" and as such thinks the "worst is in the rearview for Qiagen."

The genetic testing firm is offering approximately 2.3 million shares at $11.25 per share and plans to use the funds for general corporate purposes.

The German molecular diagnostics firm is preparing for its merger with US-based OpGen, which is slated to close in the first quarter of next year.

The firm said that in a first phase of the contract it will focus on further development of its fever test that analyzes immune system gene expression patterns.

Pages

Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.

Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.

Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.

In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.